Special Issue about Head and Neck Cancers: HPV Positive Cancers

Special Issue about Head and Neck Cancers: HPV Positive Cancers

The oropharynx has become the leading primary site for Human Papilloma Virus (HPV)-associated head and neck cancer. HPV positive oropharyngeal squamous cell carcinoma (HPV+ OSCC) has emerged as an epidemic not easily recognized by many physicians, resulting in delays in diagnosis and management. HPV...

Full description

Bibliographic Details
Main Authors: Panagiota Economopoulou, Ioannis Kotsantis, Amanda Psyrri
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:International Journal of Molecular Sciences
Subjects:
head and neck cancer
HPV
oropharyngeal cancer
de-escalation
Online Access:https://www.mdpi.com/1422-0067/21/9/3388
id doaj-744b6f0eb09a494fad803dd7dfb3e429
record_format Article
spelling doaj-744b6f0eb09a494fad803dd7dfb3e4292020-11-25T02:04:35ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-05-01213388338810.3390/ijms21093388Special Issue about Head and Neck Cancers: HPV Positive CancersPanagiota Economopoulou0Ioannis Kotsantis1Amanda Psyrri2Section of Medical Oncology, Second Department of Internal Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, 12462, Athens, GreeceSection of Medical Oncology, Second Department of Internal Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, 12462, Athens, GreeceSection of Medical Oncology, Second Department of Internal Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, 12462, Athens, GreeceThe oropharynx has become the leading primary site for Human Papilloma Virus (HPV)-associated head and neck cancer. HPV positive oropharyngeal squamous cell carcinoma (HPV+ OSCC) has emerged as an epidemic not easily recognized by many physicians, resulting in delays in diagnosis and management. HPV+ OSCC traditionally refers to younger, healthier patients with high economic status and high-risk sexual behavior and is related to improved prognosis. De-intensification strategies are being evaluated in ongoing clinical trials and if validated, might help spare severe morbidity associated with current cisplatin-based chemoradiotherapy, which is the standard of care for all patients with locally advanced head and neck cancer. On the other hand, whether HPV status represents an important prognostic factor for non-oropharyngeal sites remains to be elucidated.https://www.mdpi.com/1422-0067/21/9/3388head and neck cancerHPVoropharyngeal cancerde-escalation
collection DOAJ
language English
format Article
sources DOAJ
author Panagiota Economopoulou
Ioannis Kotsantis
Amanda Psyrri
spellingShingle Panagiota Economopoulou
Ioannis Kotsantis
Amanda Psyrri
Special Issue about Head and Neck Cancers: HPV Positive Cancers
International Journal of Molecular Sciences
head and neck cancer
HPV
oropharyngeal cancer
de-escalation
author_facet Panagiota Economopoulou
Ioannis Kotsantis
Amanda Psyrri
author_sort Panagiota Economopoulou
title Special Issue about Head and Neck Cancers: HPV Positive Cancers
title_short Special Issue about Head and Neck Cancers: HPV Positive Cancers
title_full Special Issue about Head and Neck Cancers: HPV Positive Cancers
title_fullStr Special Issue about Head and Neck Cancers: HPV Positive Cancers
title_full_unstemmed Special Issue about Head and Neck Cancers: HPV Positive Cancers
title_sort special issue about head and neck cancers: hpv positive cancers
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1661-6596
1422-0067
publishDate 2020-05-01
description The oropharynx has become the leading primary site for Human Papilloma Virus (HPV)-associated head and neck cancer. HPV positive oropharyngeal squamous cell carcinoma (HPV+ OSCC) has emerged as an epidemic not easily recognized by many physicians, resulting in delays in diagnosis and management. HPV+ OSCC traditionally refers to younger, healthier patients with high economic status and high-risk sexual behavior and is related to improved prognosis. De-intensification strategies are being evaluated in ongoing clinical trials and if validated, might help spare severe morbidity associated with current cisplatin-based chemoradiotherapy, which is the standard of care for all patients with locally advanced head and neck cancer. On the other hand, whether HPV status represents an important prognostic factor for non-oropharyngeal sites remains to be elucidated.
topic head and neck cancer
HPV
oropharyngeal cancer
de-escalation
url https://www.mdpi.com/1422-0067/21/9/3388
work_keys_str_mv AT panagiotaeconomopoulou specialissueaboutheadandneckcancershpvpositivecancers
AT ioanniskotsantis specialissueaboutheadandneckcancershpvpositivecancers
AT amandapsyrri specialissueaboutheadandneckcancershpvpositivecancers
_version_ 1724942387488227328

Similar Items